

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

CEL SCI CORP

Form: 8-K

Date Filed: 2018-06-28

Corporate Issuer CIK: 725363

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 27, 2018

CEL-SCI CORPORATION

(Exact name of Registrant as specified in its charter)

Colorado
(State or other jurisdiction of incorporation)

01-11889
(Commission File No.)

84-0916344
(IRS Employer Identification No.)

8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (703) 506-9460

N/A
(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Between April 2018 and June 2018, CEL-SCI Corporation has received \$2,133,677 through the exercise of warrants to purchase shares the Company's common stock. As of June 27, 2018, CEL-SCI had 19,518,106 outstanding shares of common stock.

CEL SCI also issued a press release, filed as Exhibit 99, concerning the exercise of these warrants.

Item 9.01 Exhibits and Financial Statement Schedules

<u>Exhibit</u>	<u>Description</u>
99	June 27, 2018 Press Release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EL-SCI CORPORATION

Date: June 27, 2018

By: /s/ Patricia B. Pritchep

Patricia B. Pritchep

Senior Vice President of Operations



Contact:

Gavin de Windt
Investor Relations Manager
Phone: 703 506-9460
Email address: gdewindt@cel-sci.com

CEL-SCI Receives \$2.1 Million from Warrant Exercises

Vienna, VA, June 27, 2018 - [CEL-SCI Corporation](#) (NYSE American: CVM), in response to shareholder questions, updates its shareholders on the amount of money received from warrant exercises since April 1, 2018. Since that time CEL-SCI has received \$2,133,677 through the exercise of warrants by investors to purchase the Company's common stock. The number of shares outstanding is 19,518,106.

About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
